素联合免疫抑制剂对紫癜性肾炎患儿血清白介素16和18水平的影响

Research on effect of corticosteroid combined with immunosuppressor on children with Henoch-Schonlein purpura nephritis

摘要:

目的  研究皮质类固醇激素及免疫抑制剂对过敏性紫癜肾炎患儿血清白介素16（IL-16）和18（IL-18）水平的影响。方法  收集60例确诊过敏性紫癜肾炎患儿，根据病情将患儿分为激素联合免疫抑制剂治疗组（A组）和常规治疗组（B组）。初次就诊收集所有患儿及A组患儿治疗结束后静脉血，采用酶联免疫吸附剂测定法（ELISA）检测A组患儿治疗前后和B组患儿治疗前血清IL-16和IL-18水平。结果  A组患儿血清IL-16为(140.04±28.26)ng/L，高于B组患儿为（75.41±17.56）ng/L（t =10.928，P =0.000）；A组患儿血清IL-18为（274.18±36.29）ng/L，高于B组患儿（145.54±33.56）ng/L（t =13.764，P =0.000）。激素联合免疫抑制剂治疗后患儿血清IL-16和IL-18水平低于治疗前（P <0.05）。结论  IL-16和IL-18可能参与紫癜性肾炎的发展，激素联合免疫抑制剂可能通过抑制IL-16和IL-18发挥治疗作用。

Abstract:

Objective To study the effect of corticosteroid combined with immunosuppressor on children with Henoch-Schonlein purpura nephritis (HSPN). Methods A total of 60 patients with HSPN were collected and divide into group A (corticosteroid combined with immunosuppressor) and group B (conventional treatment) according to condition of patients. Serum levels of IL-16 and IL-18 of all patients were detected by ELISA. Results The serum level of IL-16 and IL-18 in group A was higher than those in group B (P ＜ 0.05). After treated by corticosteroid combined with immunosuppressor, the serum levels of IL-16 and IL-18 were sig-nificantly lower than those before treatment among group A. Conclusions IL-16 and IL-18 may be involved in the development of HSPN. Corticosteroid combined with immunosuppressor may play a therapeutic role through suppressing IL-16 and IL-18.